|
0
|
|
Oat-beta-glucan potentiates anti-PD-1 efficacy through Faecalibacterium prausnitzii-derived butyrate and indole-3-propionic acid.
(linkinghub.elsevier.com)
|
Yang S
…
Liu L
Cell Host & Microbe
2026-05-29
|
#microbiome
#metabolism
#immunity
#cancer
#immunotherapy
|
|
0
|
|
Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.
(tandfonline.com)
|
Liu J
…
Qu X
Gut Microbes
2026-05-29
|
#microbiome
#metabolism
#metagenomics
#cancer
#immunotherapy
|
|
0
|
|
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.
(linkinghub.elsevier.com)
|
Xiong A
…
Zhou C
The Lancet
2026-05-29
|
#cancer
#clinical trial
#immunotherapy
#lung cancer
#pd-l1
|
|
0
|
|
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
(nejm.org)
|
Touzeau C
…
Landgren O
New England Journal of Medicine
2026-05-29
|
#antibody
#cancer
#clinical trial
#immunotherapy
|